Atossa Therapeutics, Inc. (NASDAQ:ATOS) Shares Acquired by Bank of New York Mellon Corp

Bank of New York Mellon Corp lifted its position in shares of Atossa Therapeutics, Inc. (NASDAQ:ATOS) by 3,160.5% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 411,667 shares of the company’s stock after acquiring an additional 399,041 shares during the quarter. Bank of New York Mellon Corp owned 0.33% of Atossa Therapeutics worth $490,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in the company. Cetera Advisors LLC acquired a new position in shares of Atossa Therapeutics during the first quarter worth about $72,000. Virtu Financial LLC acquired a new position in shares of Atossa Therapeutics during the first quarter worth about $151,000. Finally, Vanguard Group Inc. grew its position in Atossa Therapeutics by 1.4% during the first quarter. Vanguard Group Inc. now owns 5,753,993 shares of the company’s stock worth $10,357,000 after buying an additional 78,269 shares during the period. 12.74% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts have weighed in on the stock. Ascendiant Capital Markets upped their target price on shares of Atossa Therapeutics from $6.25 to $6.50 and gave the stock a “buy” rating in a research report on Wednesday, September 11th. HC Wainwright restated a “buy” rating and set a $6.00 target price on shares of Atossa Therapeutics in a research report on Monday, August 12th. StockNews.com lowered shares of Atossa Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, August 12th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Atossa Therapeutics in a research report on Thursday, June 20th.

Atossa Therapeutics Price Performance

Shares of NASDAQ ATOS opened at $1.40 on Wednesday. Atossa Therapeutics, Inc. has a 12-month low of $0.62 and a 12-month high of $2.31. The company has a market capitalization of $176.06 million, a PE ratio of -5.83 and a beta of 1.19. The firm’s 50-day moving average is $1.36 and its two-hundred day moving average is $1.42.

Atossa Therapeutics (NASDAQ:ATOS) last announced its quarterly earnings results on Monday, August 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.01. On average, analysts forecast that Atossa Therapeutics, Inc. will post -0.22 EPS for the current fiscal year.

Atossa Therapeutics Profile

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.